Status:
TERMINATED
Serum GFAP and UCHL1: Evaluation of Their Predictive Value for SAH
Lead Sponsor:
The Royal Wolverhampton Hospitals NHS Trust
Conditions:
Subarachnoid Haemorrhage (SAH)
Eligibility:
All Genders
18+ years
Brief Summary
To verify the analytical performance of GFAP and UCH-L1 biomarkers marketed by Abbott Diagnostics and to assess diagnostic accuracy of these biomarkers in predicting subarachnoid haemorrhage
Detailed Description
Subarachnoid haemorrhage (SAH) refers to blood entering the subarachnoid space and may be due to aneurysmal or non-aneurysmal causes. Patients with SAH characteristically present with a sudden onset '...
Eligibility Criteria
Inclusion
- Patients ≥18 years old, who have had an LP with a serum sample taken within 24 hours of the LP.
Exclusion
- \-
Key Trial Info
Start Date :
January 16 2025
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 28 2025
Estimated Enrollment :
144 Patients enrolled
Trial Details
Trial ID
NCT06581757
Start Date
January 16 2025
End Date
April 28 2025
Last Update
June 15 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
New Cross Hospital
Wolverhampton, West Midlands, United Kingdom, WV10 0QP